Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

David J. Vaughn, Catherine M. Broome, Maha Hussain, John C. Gutheil, Avi Markowitz

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

Purpose: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Patients and Methods: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg/m2 by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments. Results: The study enrolled 31 patients. Mean age was 66 years, and 45% of patients had three or more involved metastatic sites. Only 26% of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m2. Three patients achieved a partial response (10%; 95% confidence interval, 0% to 20%). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon. Conclusion: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered.

Original languageEnglish (US)
Pages (from-to)937-940
Number of pages4
JournalJournal of Clinical Oncology
Volume20
Issue number4
DOIs
StatePublished - Feb 15 2002
Externally publishedYes

Fingerprint

Paclitaxel
Neoplasms
Drug Therapy
Intravenous Infusions
Disease Progression
Therapeutics
Confidence Intervals
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. / Vaughn, David J.; Broome, Catherine M.; Hussain, Maha; Gutheil, John C.; Markowitz, Avi.

In: Journal of Clinical Oncology, Vol. 20, No. 4, 15.02.2002, p. 937-940.

Research output: Contribution to journalArticle

Vaughn, David J. ; Broome, Catherine M. ; Hussain, Maha ; Gutheil, John C. ; Markowitz, Avi. / Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 4. pp. 937-940.
@article{bafc9d69156849e9b0dae874603a292f,
title = "Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer",
abstract = "Purpose: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Patients and Methods: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg/m2 by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments. Results: The study enrolled 31 patients. Mean age was 66 years, and 45{\%} of patients had three or more involved metastatic sites. Only 26{\%} of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m2. Three patients achieved a partial response (10{\%}; 95{\%} confidence interval, 0{\%} to 20{\%}). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon. Conclusion: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered.",
author = "Vaughn, {David J.} and Broome, {Catherine M.} and Maha Hussain and Gutheil, {John C.} and Avi Markowitz",
year = "2002",
month = "2",
day = "15",
doi = "10.1200/JCO.20.4.937",
language = "English (US)",
volume = "20",
pages = "937--940",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

AU - Vaughn, David J.

AU - Broome, Catherine M.

AU - Hussain, Maha

AU - Gutheil, John C.

AU - Markowitz, Avi

PY - 2002/2/15

Y1 - 2002/2/15

N2 - Purpose: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Patients and Methods: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg/m2 by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments. Results: The study enrolled 31 patients. Mean age was 66 years, and 45% of patients had three or more involved metastatic sites. Only 26% of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m2. Three patients achieved a partial response (10%; 95% confidence interval, 0% to 20%). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon. Conclusion: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered.

AB - Purpose: We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Patients and Methods: Patients with urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and had evidence of disease progression were eligible for enrollment. Patients received paclitaxel 80 mg/m2 by 1-hour intravenous infusion weekly. A cycle of therapy consisted of four weekly treatments. Results: The study enrolled 31 patients. Mean age was 66 years, and 45% of patients had three or more involved metastatic sites. Only 26% of patients had responded to prior chemotherapy. The median number of cycles delivered was three (range, one to eight) at a mean weekly paclitaxel dose of 79 mg/m2. Three patients achieved a partial response (10%; 95% confidence interval, 0% to 20%). Median time to progression was 2.2 months, and median overall survival time was 7.2 months. Therapy was well tolerated with minimal hematologic toxicity. Grade 3 nonhematologic toxicities were also uncommon. Conclusion: Although the overall response rate to weekly paclitaxel in patients with previously treated advanced urothelial cancer was modest, the chemotherapy-refractory nature of the study population should be considered.

UR - http://www.scopus.com/inward/record.url?scp=0037083580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037083580&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.4.937

DO - 10.1200/JCO.20.4.937

M3 - Article

VL - 20

SP - 937

EP - 940

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -